SLC26A7 Activators
SLC26A7 activators belong to a class of compounds that specifically target the Solute Carrier 26A7 (SLC26A7) protein, a member of the SLC26 transporter family. The SLC26A7 gene encodes for a chloride ion transporter that plays a crucial role in the regulation of cellular chloride transport. These activators are designed to modulate the activity of SLC26A7, thereby influencing its function in facilitating the movement of chloride ions across cell membranes. The SLC26 family, including SLC26A7, is implicated in various physiological processes, such as ion homeostasis, acid-base balance, and fluid secretion in tissues.
SLC26A7 activators possess unique structural features that enable them to interact selectively with the SLC26A7 protein, modulating its conformation and, consequently, its activity. These compounds may function by binding to specific sites on the SLC26A7 transporter, inducing a conformational change that enhances its chloride transport capabilities. Understanding the precise mechanism of action of SLC26A7 activators at the molecular level is an active area of research, as it holds promise for elucidating the intricacies of chloride ion transport and cellular homeostasis. Researchers are keenly exploring the structural and functional aspects of these activators to gain insights into the broader regulatory network involving SLC26A7 and its potential implications in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin can activate adenylate cyclase, leading to increased cAMP levels, which may indirectly enhance SLC26A7 activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP, a cAMP analog, can potentially stimulate SLC26A7 indirectly via protein kinase A (PKA). | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, a nonspecific inhibitor of phosphodiesterases, can raise cAMP levels, thus indirectly activating SLC26A7. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein can inhibit tyrosine kinases, which may lead to an increase in SLC26A7 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a potent protein kinase inhibitor, can potentially activate SLC26A7 indirectly by inhibiting protein kinases that suppress SLC26A7. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin can inhibit tyrosine kinases, potentially leading to an increase in SLC26A7 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059, a selective MEK inhibitor, can indirectly modulate SLC26A7 activity by influencing the MAPK signaling pathway. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $32.00 | 3 | |
Niflumic acid is a Cl-/HCO3- exchanger inhibitor, which can indirectly upregulate SLC26A7 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, can indirectly influence SLC26A7 activity by modulating PI3K/Akt signaling. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide, a loop diuretic, can indirectly influence SLC26A7 activity by modulating electrolyte balance. | ||||||